Erasca Inc. (ERAS)
1.55
0.07 (4.73%)
At close: Mar 27, 2025, 3:59 PM
1.54
-0.85%
Pre-market: Mar 28, 2025, 04:03 AM EDT
4.73% (1D)
| Bid | 1.41 |
| Market Cap | 440.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.58M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -2.25 |
| Forward PE | -3.07 |
| Analyst | Buy |
| Ask | 1.58 |
| Volume | 1,167,623 |
| Avg. Volume (20D) | 1,455,059 |
| Open | 1.48 |
| Previous Close | 1.48 |
| Day's Range | 1.46 - 1.57 |
| 52-Week Range | 1.23 - 3.45 |
| Beta | 1.22 |
About ERAS
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2021
Employees 126
Stock Exchange NASDAQ
Ticker Symbol ERAS
Website https://www.erasca.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ERAS stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 221.54% from the latest price.
Stock Forecasts6 months ago
+7.87%
Erasca shares are trading higher after the company...
Unlock content with
Pro Subscription
10 months ago
+6.49%
Erasca shares are trading higher after the company announced that it entered into exclusive license agreements for two preclinical RAS programs.
